Meera E Modi1, Larry J Young. 1. Center for Translational Social Neuroscience, Department of Psychiatry and Behavioral Sciences, Division of Behavioral Neuroscience and Psychiatric Disorders, Yerkes National Primate Research Center, Emory University, 954 Gatewood Road, Atlanta, GA 30329, USA. mmodi@emory.edu
Abstract
BACKGROUND: There are no drugs that specifically target the social deficits of autism spectrum disorders (ASD). This may be due to a lack of behavioral paradigms in animal models relevant to ASD. Partner preference formation in the prairie vole represents a social cognitive process involving socially reinforced learning. D-cycloserine (DCS) is a cognitive enhancer that acts at the N-methyl-D-aspartate receptor to promote learning. If DCS enhances socially reinforced learning in the partner preference paradigm, it may be useful in combination with behavioral therapies for enhancing social functioning in ASD. METHODS: Female prairie and meadow voles were given DCS either peripherally or directly into one of three brain regions: nucleus accumbens, amygdala, or caudate putamen. Subjects were then cohabited with a male vole under conditions that do not typically yield a partner preference. The development of a preference for that stimulus male vole over a novel male vole was assessed using a partner preference test. RESULTS: A low dose of DCS administered peripherally enhanced preference formation in prairie voles but not meadow voles under conditions in which it would not otherwise occur. These effects were replicated in prairie voles by microinfusions of DCS into the nucleus accumbens, which is involved in reinforcement learning, and the amygdala, which is involved in social information processing. CONCLUSIONS: Partner preference in the prairie vole may provide a behavioral paradigm with face, construct, and predictive validity for identifying prosocial pharmacotherapeutics. D-cycloserine may be a viable treatment strategy for social deficits of ASD when paired with social behavioral therapy.
BACKGROUND: There are no drugs that specifically target the social deficits of autism spectrum disorders (ASD). This may be due to a lack of behavioral paradigms in animal models relevant to ASD. Partner preference formation in the prairie vole represents a social cognitive process involving socially reinforced learning. D-cycloserine (DCS) is a cognitive enhancer that acts at the N-methyl-D-aspartate receptor to promote learning. If DCS enhances socially reinforced learning in the partner preference paradigm, it may be useful in combination with behavioral therapies for enhancing social functioning in ASD. METHODS: Female prairie and meadow voles were given DCS either peripherally or directly into one of three brain regions: nucleus accumbens, amygdala, or caudate putamen. Subjects were then cohabited with a male vole under conditions that do not typically yield a partner preference. The development of a preference for that stimulus male vole over a novel male vole was assessed using a partner preference test. RESULTS: A low dose of DCS administered peripherally enhanced preference formation in prairie voles but not meadow voles under conditions in which it would not otherwise occur. These effects were replicated in prairie voles by microinfusions of DCS into the nucleus accumbens, which is involved in reinforcement learning, and the amygdala, which is involved in social information processing. CONCLUSIONS: Partner preference in the prairie vole may provide a behavioral paradigm with face, construct, and predictive validity for identifying prosocial pharmacotherapeutics. D-cycloserine may be a viable treatment strategy for social deficits of ASD when paired with social behavioral therapy.
Authors: Suma Jacob; Camille W Brune; C S Carter; Bennett L Leventhal; Catherine Lord; Edwin H Cook Journal: Neurosci Lett Date: 2007-02-03 Impact factor: 3.046
Authors: David J Posey; Deborah L Kem; Naomi B Swiezy; Thayne L Sweeten; Ryan E Wiegand; Christopher J McDougle Journal: Am J Psychiatry Date: 2004-11 Impact factor: 18.112
Authors: Joe A Hettinger; Xudong Liu; Charles E Schwartz; Ron C Michaelis; Jeanette J A Holden Journal: Am J Med Genet B Neuropsychiatr Genet Date: 2008-07-05 Impact factor: 3.568
Authors: Mariken de Krom; Wouter G Staal; Roel A Ophoff; Judith Hendriks; Jan Buitelaar; Barbara Franke; Maretha V de Jonge; Patrick Bolton; David Collier; Sarah Curran; Herman van Engeland; Jan M van Ree Journal: Biol Psychiatry Date: 2008-12-05 Impact factor: 13.382
Authors: Adam J Guastella; Stewart L Einfeld; Kylie M Gray; Nicole J Rinehart; Bruce J Tonge; Timothy J Lambert; Ian B Hickie Journal: Biol Psychiatry Date: 2009-11-07 Impact factor: 13.382
Authors: Alaine C Keebaugh; Catherine E Barrett; Jamie L Laprairie; Jasmine J Jenkins; Larry J Young Journal: Soc Neurosci Date: 2015-05-07 Impact factor: 2.083
Authors: James P Burkett; Lauren L Spiegel; Kiyoshi Inoue; Anne Z Murphy; Larry J Young Journal: Neuropsychopharmacology Date: 2011-07-06 Impact factor: 7.853
Authors: Tatiana M Kazdoba; Prescott T Leach; Mu Yang; Jill L Silverman; Marjorie Solomon; Jacqueline N Crawley Journal: Curr Top Behav Neurosci Date: 2016
Authors: Karen L Bales; Allison M Perkeybile; Olivia G Conley; Meredith H Lee; Caleigh D Guoynes; Griffin M Downing; Catherine R Yun; Marjorie Solomon; Suma Jacob; Sally P Mendoza Journal: Biol Psychiatry Date: 2012-10-16 Impact factor: 13.382
Authors: Catherine E Barrett; Alaine C Keebaugh; Todd H Ahern; Caroline E Bass; Ernest F Terwilliger; Larry J Young Journal: Horm Behav Date: 2013-01-28 Impact factor: 3.587